Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELMD Electromed	$18.47 +1.3%	$20.47	$13.74 ▼ $35.56	$154.89M	0.41	87,828 shs	11,673 shs
EMBC Embecta	$10.08 +3.1%	$10.45	$9.20 ▼ $21.48	$589.08M	1.08	503,883 shs	75,802 shs
IRMD iRadimed	$56.46 -0.4%	$57.62	$42.34 ▼ $63.29	$720.65M	0.91	44,014 shs	4,222 shs
RXST RxSight	$7.44 +1.2%	$13.32	$6.32 ▼ $58.23	$302.16M	1.21	818,163 shs	351,594 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELMD Electromed	0.00%	-4.45%	-11.20%	-19.41%	+15.82%
EMBC Embecta	0.00%	-6.59%	+0.10%	-10.36%	-25.74%
IRMD iRadimed	0.00%	-1.53%	-2.66%	+11.64%	+25.42%
RXST RxSight	0.00%	-8.13%	-46.00%	-48.24%	-84.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELMD Electromed	0.947 of 5 stars	2.0	1.0	0.0	0.0	0.6	1.7	1.3
EMBC Embecta	4.6377 of 5 stars	3.2	3.0	3.3	0.0	1.7	3.3	3.8
IRMD iRadimed	4.5232 of 5 stars	3.5	3.0	2.5	4.4	0.0	3.3	1.9
RXST RxSight	2.5419 of 5 stars	4.0	1.0	0.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELMD Electromed	4.00	Strong Buy	$38.00	105.74% Upside
EMBC Embecta	2.33	Hold	$19.00	88.49% Upside
IRMD iRadimed	3.00	Buy	$72.00	27.53% Upside
RXST RxSight	1.91	Reduce	$17.50	135.37% Upside

Current Analyst Ratings Breakdown

Latest ELMD, IRMD, EMBC, and RXST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$13.00 ➝ $12.00
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00
7/9/2025	RXST RxSight	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/9/2025	RXST RxSight	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$25.00 ➝ $9.00
7/9/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
7/9/2025	RXST RxSight	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/23/2025	EMBC Embecta	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELMD Electromed	$61.44M	2.52	$0.45 per share	41.36	$5.10 per share	3.62
EMBC Embecta	$1.12B	0.52	$3.44 per share	2.93	($12.80) per share	-0.79
IRMD iRadimed	$73.24M	9.81	$1.58 per share	35.83	$6.85 per share	8.24
RXST RxSight	$139.93M	2.16	N/A	N/A	$6.98 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELMD Electromed	$5.15M	$0.79	24.63	∞	N/A	11.34%	15.71%	13.37%	N/A
EMBC Embecta	$78.30M	$0.90	11.20	3.28	0.63	4.89%	-19.67%	12.27%	8/8/2025 (Estimated)
IRMD iRadimed	$19.23M	$1.55	36.55	28.23	N/A	26.33%	23.28%	20.59%	7/30/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.67	N/A	N/A	N/A	-17.90%	-9.54%	-8.51%	8/7/2025 (Estimated)

Latest ELMD, IRMD, EMBC, and RXST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q3 2025	EMBC Embecta	$0.7720	N/A	N/A	N/A	$278.15 million	N/A
8/7/2025	Q2 2025	IRMD iRadimed	$0.45	N/A	N/A	N/A	N/A	N/A
8/7/2025	Guidance Update	RXST RxSight	-$0.0363	N/A	N/A	N/A	$39.78 million	N/A
5/9/2025	Q2 2025	EMBC Embecta	$0.66	$0.70	+$0.04	$0.40	$261.77 million	$259.00 million
5/7/2025	Q1 2025	RXST RxSight	-$0.03	-$0.03	N/A	-$0.20	$38.74 million	$37.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELMD Electromed	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	5.95%	N/A	66.67%	N/A
IRMD iRadimed	$0.68	1.20%	N/A	43.87%	1 Years
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Latest ELMD, IRMD, EMBC, and RXST Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/5/2025	EMBC Embecta	quarterly	$0.15	4.51%	5/28/2025	5/28/2025	6/13/2025
5/5/2025	IRMD iRadimed	quarterly	$0.17	1.3%	5/20/2025	5/20/2025	5/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELMD Electromed	N/A	5.10	4.74
EMBC Embecta	N/A	2.48	1.83
IRMD iRadimed	N/A	8.87	7.62
RXST RxSight	N/A	12.68	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELMD Electromed	40.82%
EMBC Embecta	93.83%
IRMD iRadimed	92.34%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
ELMD Electromed	14.00%
EMBC Embecta	0.42%
IRMD iRadimed	36.80%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELMD Electromed	160	8.39 million	7.36 million	Optionable
EMBC Embecta	2,100	58.44 million	58.20 million	Optionable
IRMD iRadimed	110	12.72 million	8.04 million	Optionable
RXST RxSight	220	40.64 million	36.75 million	Optionable

ELMD, IRMD, EMBC, and RXST Headlines

Recent News About These Companies

RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm

2 hours ago | prnewswire.com

RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law ...

July 20 at 8:26 AM | gurufocus.com

RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company

July 20 at 7:08 AM | globenewswire.com

What Does The Future Hold For RxSight, Inc. (NASDAQ:RXST)? These Analysts Have Been Cutting Their Estimates

July 19 at 8:38 PM | finance.yahoo.com

New York State Common Retirement Fund Has $10.28 Million Stock Position in RxSight, Inc. (NASDAQ:RXST)

July 19 at 4:22 AM | marketbeat.com

RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm

July 18 at 1:43 PM | gurufocus.com

RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm

July 18 at 1:06 PM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ...

July 18 at 12:08 PM | gurufocus.com

RXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud ...

July 18 at 10:31 AM | gurufocus.com

RXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud Investigation – Contact BFA Law if You Lost Money

July 18 at 9:07 AM | globenewswire.com

RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses

July 17, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

July 17, 2025 | prnewswire.com

RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 16, 2025 | businesswire.com

Morgan Stanley Downgrades RxSight (RXST)

July 16, 2025 | msn.com

RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces Investigation into RxSight, Inc. (RXST) and Encourages Investors to Contact the Firm

July 15, 2025 | globenewswire.com

Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders

July 15, 2025 | globenewswire.com

Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

July 15, 2025 | businesswire.com

Morgan Stanley Downgrades RxSight (NASDAQ:RXST) to Equal Weight

July 15, 2025 | marketbeat.com

RxSight (NASDAQ:RXST) Earns Hold Rating from Jefferies Financial Group

July 13, 2025 | americanbankingnews.com

Brokerages Set RxSight, Inc. (NASDAQ:RXST) PT at $30.20

July 13, 2025 | americanbankingnews.com

RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices ...

July 12, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD, IRMD, EMBC, and RXST Company Descriptions

Electromed NYSE:ELMD

$18.47 +0.24 (+1.32%)

As of 11:44 AM Eastern

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Embecta NASDAQ:EMBC

$10.08 +0.30 (+3.07%)

As of 11:43 AM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

iRadimed NASDAQ:IRMD

$56.46 -0.23 (-0.41%)

As of 11:42 AM Eastern

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

RxSight NASDAQ:RXST

$7.43 +0.08 (+1.03%)

As of 11:44 AM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time